Navigation Links
arGEN-X Appoints Alain Thibault as Chief Medical Officer and Koos Rasser as IP Counsel
Date:3/19/2012

ROTTERDAM, the Netherlands and GHENT, Belgium, March 19, 2012 /PRNewswire/ --

arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody™ platform, announces today that it has strengthened its management team with two key hires. Alain Thibault, MD joins the Company as Chief Medical Officer, while Jacobus (Koos) Rasser, PhD, JD will serve as IP Counsel.

Dr. Alain Thibault has gained a wealth of clinical development experience in oncology, both in the US and Europe, in a career spanning more than 15 years. Prior to joining arGEN-X, Dr.Thibault was therapeutic area head of Oncology at Regeneron Pharmaceuticals where he was responsible for clinical development, product strategy and portfolio management, as well as coordination of the collaboration with Sanofi to develop fully human antibody products for multiple cancer indications. While at Regeneron, Dr. Thibault led the clinical development of VEGF Trap (aflibercept) as well as the fully human antibody products REGN 421 and REGN 910. Dr. Thibault has extensive clinical development expertise across all stages of biopharmaceutical clinical development, having previously held senior research positions at Johnson & Johnson and Hoffman-La Roche before joining Regeneron.

Koos Rasser, PhD, JD brings over 30 years of experience in the development and commercialization of global intellectual property portfolios. Before joining arGEN-X, Dr. Rasser was senior partner at the global IP law firm Howrey LLP and founded its London practice. Among his clients in the pharma/biotech field were Biogen Idec, Millennium Pharmaceuticals, Eppendorf, Schering Plough and Amersham. He also acted as interim IP Director at Akzo Nobel's Organon Division. Prior to his tenure at Howrey, Dr. Rasser was head of the global IP organization at Procter & Gamble, where he was responsible for a portfolio of more than 2,000 patent families protecting over a dozen billion-dollar brands.

Welcoming Alain and Koos to the Company, Tim Van Hauwermeiren, Chief Executive Officer at arGEN-X said: "We are delighted to have attracted such high caliber individuals as Alain and Koos to arGEN-X at such an exciting time in our evolution. As the quality and productivity of our SIMPLE Antibody™ platform translates consistently into clinical development opportunities and valuable new intellectual property, their expertise will be fundamental to attaining our ambitious business goals and reaching our next value inflection point as a Company."

About arGEN-X - http://www.arGEN-X.com

arGEN-X is a preclinical stage biopharmaceutical company that is rapidly leveraging the power of its broadly applicable, proprietary SIMPLE Antibody™ platform to generate fully human antibodies with differentiated qualities and outstanding therapeutic potential. The platform excels in delivering large panels of ultra-potent, functionally diverse antibodies against complex disease targets, especially cell surface receptors and highly conserved proteins. The superior choice that arGEN-X brings to antibody discovery enables it to prioritise leads with best-in-class therapeutic properties, thereby increasing the probability of development success. Antibody leads generated from the SIMPLE Antibody™ platform have outstanding physicochemical properties and consistent manufacturability, enabling a seamless transition from discovery into development. arGEN-X has validated its technology on multiple diverse classes of target to date and has successfully delivered in its collaboration with Eli Lilly & Co.. Recently, arGEN-X announced a strategic alliance with the specialty pharmaceutical company Shire, focused on the discovery and development of monoclonal antibody therapeutics to treat rare diseases.

Most recently, arGEN-X has obtained an exclusive global license to a technology named NHance™, to optimize the pharmacokinetic half-life of its SIMPLE Antibodies and maximize their therapeutic utility.

The SIMPLE Antibody™ and NHance™ platforms are covered by broad patent claims, enjoyingan independent, unencumbered patent position and are free of target gatekeeping restrictions.

SIMPLE stands for Superior Immunodiversity with Minimal Protein Lead Engineering.

arGEN-X™, SIMPLE Antibody™ and NHance™ are deposited trademarks of arGEN-X BV.

For licensing inquiries about NHance™, please contact

Business.Development@arGEN-X.com

For further information, please contact:

Citigate Dewe Rogerson
David Dible
Mark Swallow
Nina Enegren
T: +44(0)207-282-2949/2948/1050
E:david.dible@citigatedr.co.uk


arGEN-X
Tim Van Hauwermeiren, MSc, eMBA
Chief Executive Officer
T: +31-6-122-85-257
E: tim.vh@arGEN-X.com

Debbie Allen, Ph.D.
Senior Director, Business Development

T: +44(0)7974-979479
E: dallen@arGEN-X.com


'/>"/>
SOURCE arGEN-X
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. arGEN-X Concludes EUR 12.5 Million Series A Financing Round
2. arGEN-X SIMPLE Antibody(TM) Platform set to Transform Therapeutic Antibody Discovery & Development
3. arGEN-X Granted Broad Patent Covering its Unique SIMPLE Antibody(TM) Platform
4. arGEN-X Announces Non-Exclusive License With BioWa for POTELLIGENT® Technology
5. arGEN-X Presents Significant Progress at BioPharm America 2011
6. arGEN-X raises EUR 27.5 million (USD 37 million) in oversubscribed Series B Round
7. Argen-X Launches NHance™ Technology to Generate Better Human Antibody Therapies
8. Quark Pharmaceuticals Appoints New Chief Medical Officer
9. West Pharmaceutical Services, Inc. Appoints New Director
10. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
11. Curemark Appoints Preeminent Pediatrics Gastroenterologist
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... synthetic Fentanyl arrived on the streets in 2015, dealers were ... samples, inviting would-be customers to test a newly-created batch. They ... The rapidly-growing demand for the powerful ... has racked up a staggering death toll across ... fentanyl sales reveals that they have sold nearly 400 grams ...
(Date:1/16/2017)... and PUNE, India , January ... by Allied Market Research, titled, "Vital Signs Monitoring Devices Market ... Forecast, 2014-2022", projects that the global vital signs monitoring devices ... expected to reach $5,491 million by 2022, growing at a ... America was the leading regional market in global ...
(Date:1/16/2017)... 2017 The report "Cellulose ... (Methyl, Ethyl, Hydroxyethyl, Hydroxypropyl, Carboxymethyl Cellulose), Application ... Coatings & Paints), Region - Global Forecast ... was valued at USD 4.51 Billion in ... 6.41 Billion by 2021, at a CAGR ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... ... Today, FloSports , a global leader in live digital sports and ... a long-term extension of their media partnership. The partnership, which began in 2013, will ... premier events exclusively on FloWrestling.com as well as usage of the FloArena meet management ...
(Date:1/16/2017)... Costa Mesa, California (PRWEB) , ... January 16, 2017 , ... ... Since 2014, Dr. Beazley has served on CalSouthern’s Board of Trustees and as a ... Sciences. In addition, he has been a professor of psychology at Pepperdine University, where ...
(Date:1/16/2017)... ... January 16, 2017 , ... Anybody who may be looking for ... new video released by Serenity Recovery, a holistic treatment center for addiction located in ... features footage and testimonials from patients and staff that visited the 2016 Recovery Palooza ...
(Date:1/16/2017)... ... January 16, 2017 , ... ... the newly updated International Audit Protocol Consortium (IAPC) EHS audit protocol for ... understand the scope of their EHS regulatory obligations and rapidly collect, share, archive, ...
(Date:1/16/2017)... ... January 16, 2017 , ... Board-certified oculoplastic ... Journal , the official journal of The American Society for Aesthetic Plastic Surgery, ... The procedure is designed to correct drooping, retracted lower eyelids, which usually result ...
Breaking Medicine News(10 mins):